Compare TRVG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | ABEO |
|---|---|---|
| Founded | 2005 | 1974 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 280.2M |
| IPO Year | 2015 | 2005 |
| Metric | TRVG | ABEO |
|---|---|---|
| Price | $2.77 | $4.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.09 | ★ $18.75 |
| AVG Volume (30 Days) | 32.9K | ★ 1.0M |
| Earning Date | 01-01-0001 | 07-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | $1,589.77 |
| P/E Ratio | $16.98 | ★ $4.55 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.71 | $3.93 |
| 52 Week High | $5.83 | $7.54 |
| Indicator | TRVG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 41.06 |
| Support Level | $2.77 | $4.53 |
| Resistance Level | $2.93 | $5.62 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 16.00 | 32.10 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.